Abstract
Background: Factor (F)XII triggers contact activation by binding to foreign surfaces, with the epidermal growth factor-like 1 (EGF-1) domain being the primary binding site. Blocking FXII surface-binding might hold therapeutic value to prevent medical device–induced thrombosis. Objectives: To unravel and prevent EGF-1–mediated FXII surface-binding with a variable domain of heavy
... read more